The short answer is that no one knows, and the reasons are on FDA's own record. In 2024 FDA reviewed both peptides for its compounding list and wrote up every safety signal it could find [3] [5]. Those reviews are more specific than the "mild side effects" line you'll see on clinic pages. For what each peptide is and claims to do, see the CJC-1295 guide and the ipamorelin guide.
Safety is not established for either peptide, or for the pair
The selected CJC reports are small and predominantly male, with overlapping participants. The main published ipamorelin safety trial involved postoperative IV use. A newer observational program lists ipamorelin among multiple interventions but has no results. None establishes this combination’s safety.
| Peptide | Event | Rate | Source |
|---|---|---|---|
| CJC-1295 (with DAC) | Headache | 63% vs 14% on placebo | FDA briefing, Teichman 2006 study 1 |
| CJC-1295 (with DAC) | Flushing, warmth, brief low blood pressure | 40% at low dose to 100% at high dose | FDA briefing, Teichman 2006 study 2 |
| CJC-1295 (with DAC) | Injection-site reactions | About 70%, rare on placebo | FDA briefing, Teichman 2006 study 1 |
| CJC-1295 (with DAC) | Diarrhea | 43%, treated group only | FDA briefing, Teichman 2006 study 1 |
| CJC-1295 (with DAC) | Faster heart rate | Dose-dependent; no rate given | FDA briefing, Ionescu 2006 |
| CJC-1295 (with DAC) | Death from heart attack | 1 participant, unpublished trial of 192 | FDA briefing, press reports |
| Ipamorelin (by vein) | Serious adverse events | 17.9% vs 15.5% on placebo | FDA briefing, Beck 2014 |
| Ipamorelin (by vein) | High blood sugar at discharge | 14.3% vs 8.6% on placebo | FDA briefing, Beck 2014 |
| Ipamorelin (by vein) | Deaths | 2 treated patients; relation unclear | FDA briefing, Beck 2014 |
Sources: FDA Pharmacy Compounding Advisory Committee briefings for CJC-1295 (December 4, 2024) and ipamorelin (October 29, 2024).
CJC-1295 caused flushing, headaches and faster heart rates in trials
FDA summarizes 63 reported CJC exposures,87% male and 73% single-injection, across publications that include an overlapping 11-man subset [3]. In Teichman study 1,33 of 35 treated participants reported an adverse event versus2 of 7 placebo participants; the percentages were 94% and 29% [8].
Flushing tracked the dose. In the second trial, it struck 40% of people after a low dose and 100% after a high dose, within 30 minutes and lasting one to two hours [3]. A separate study in healthy men recorded a dose-dependent rise in heart rate [9]. FDA's safety-risks page sums it up: it "has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction" [7].
Flushing was the most common systemic reaction in these trials. If it happens to you, tell your prescriber; how to manage it is a medical decision, not a home adjustment.
FDA's review describes one death in an unpublished CJC-1295 trial
FDA's briefing describes one participant in an unpublished HIV trial of CJC-1295 with DAC who had a heart attack two hours after an 11th weekly dose and died about an hour later. The attending physician's most likely explanation was undiagnosed coronary artery disease. FDA's account relies on press reports from the time, and the trial, which enrolled 192 people, was stopped and its data never published [3].
That account does not show CJC-1295 caused the death. It does show why FDA wrote that some of these effects "might inform how the substance should be administered and monitored in certain populations, such as those at risk for falls or those with heart disease" [3].
The published ipamorelin safety trial involved surgery patients
FDA found one clinical study with ipamorelin safety data: a trial that enrolled 117 hospitalized adults after bowel surgery, with 114 receiving ipamorelin or placebo by intravenous infusion for up to a week [5]. The trial was sponsored by Helsinn Therapeutics, a drug company, and the authors called the drug well tolerated [10].
FDA's reading is more cautious. Serious adverse events hit 17.9% of the ipamorelin group and 15.5% of the placebo group. Two ipamorelin patients, both operated on for colon cancer, died after leaks at the surgical join. FDA says "it is unclear whether the deaths reported in the above study were related to ipamorelin," but that the deaths, with higher rates of low potassium and high blood sugar, raise safety concerns [5].
Clinics sell ipamorelin as an injection under the skin, not an infusion. FDA's conclusion on that route is blunt: "There are no safety data for ipamorelin (free base) and ipamorelin acetate administered by the nominator proposed SC ROA" [5]. SC ROA means the subcutaneous route.
FDA also flags immune reactions. Peptides can clump together or carry manufacturing impurities, and FDA says this risk may rise when they are injected [5]. Ipamorelin acetate is still in Category 2 of FDA's list for outsourcing facilities, the 503B list [7].
The located evidence does not establish combination safety
An October 22, 2026 Europe PMC search returned 23 indexed records, including reviews, analytical reports and preprints; none reported a clinical trial administering this combination [2]. The current ClinicalTrials.gov combination query returned no studies [1]. These searches do not establish that every unpublished experiment is known; they establish the limits of the located clinical evidence.
Both peptides push the body to release more growth hormone, by different routes. Whether stacking them adds risk is untested, so any "synergistic and safe" claim is a claim, not a finding.
The CJC-1295 you'd get may not be the one studied
The human CJC-1295 reports reviewed by FDA used the long-acting form with a drug affinity complex (DAC) attached. FDA found no clinical safety information in its reviewed sources for the version without DAC, which it calls CJC-1295 free base, or for the salt forms [3].
Names make this worse. FDA counted at least nine names in use for five distinct CJC-1295 substances and called the inconsistency "a safety risk for patients as they may be dosed with a different BDS than the physician ordered" [3]. BDS means bulk drug substance, the raw ingredient. Ask exactly which molecule a product contains.
No trial measured weight gain with either peptide
None of the human studies FDA summarized reported weight change for either peptide. FDA does point to a broader pattern: drugs that raise growth hormone carry label risks that include fluid retention, glucose intolerance, intracranial hypertension and an increased risk of neoplasms [5]. Puffiness or swelling would fit that pattern, but no trial of these peptides has measured it.
FDA's advisers voted against compounding both peptides
In October 2024, FDA's Pharmacy Compounding Advisory Committee voted on adding ipamorelin to the list of bulk substances 503A pharmacies may use. The tally for each form was "zero yeses, 12 noes, and 1 abstention" [6]. In December 2024, the committee voted 0-13 against four forms of CJC-1295 and 1-12 against the acetate form [4].
Neither peptide is FDA-approved, and neither is on the 503A bulks list. For contrast, BPC-157 went before the same committee in July 2026, covered in is BPC-157 FDA-approved, while tesamorelin, a related growth hormone-releasing hormone analog, is approved as a brand drug: see is tesamorelin FDA-approved.
Some people have more reason to ask before trying either
- Do you have heart disease or low blood pressure? CJC-1295 raised heart rate and caused flushing with brief drops in blood pressure, and FDA named heart disease as a group needing study.
- Do you have diabetes or prediabetes? High blood sugar was more common on ipamorelin, and glucose intolerance is a known risk of drugs that raise growth hormone.
- Have you had cancer? FDA notes that approved growth hormone products list an increased risk of neoplasms. The postoperative ipamorelin trial included colon-cancer surgery patients; that does not establish long-term cancer risk or routine use in cancer survivors.
- Are you a tested athlete? WADA lists both under S2.2.4, growth hormone releasing factors, prohibited at all times [11].
Any provider offering these peptides should be able to answer what molecule you would get and who makes it. These are the questions behind every check on this site; how we check sets them out.
A current observational registry, NCT07717866, lists 52 actual participants in a multimodal veterans program and names ipamorelin among several physiological-supplementation options. It has no posted results and does not isolate ipamorelin, establish its route-specific safety or test this CJC combination [12].